Atlantic Healthcare announces Chairman to step down as company enters next phase of preparing for product commercialisation


Cambridge, UK; March 22, 2017. Atlantic Healthcare plc (“Atlantic Healthcare”), an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal (GI) disorders, is continuing to make good progress towards delivering the…

Read More

Atlantic Healthcare confirms alicaforsen targets TLR-9, providing a second mechanism of action to treat new and existing inflammatory indications


Patent applications filed based on novel discovery, which may provide biological rationale for alicaforsen’s previously observed durable response in inflammatory bowel disease Cambridge, UK; February 28, 2017. Atlantic Healthcare plc (“Atlantic…

Read More

Atlantic Healthcare to present at BIO CEO & Investor Conference 2017


Leadership Team available for meetings in New York, February 13-14 and 21 Cambridge, UK; February 6 2017. Atlantic Healthcare plc (“Atlantic Healthcare”), an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal (GI)…

Read More

Atlantic Healthcare receives FDA agreement to initiate rolling submission of its New Drug Application for alicaforsen in the treatment of pouchitis


FDA to accept sections of the regulatory application ahead of final Phase 3 data Cambridge, UK; January 24, 2017. Atlantic Healthcare plc ("Atlantic Healthcare"), an emerging trans-Atlantic pharmaceutical company with a core focus on…

Read More